WP
CUE icon

WealthShield Partners’s Cue Biopharma CUE Stock Holding History

WealthShield Partners’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-998
Closed -$146K – 299
2022
Q1 		$146K Buy
998
+617
+162% +$131K 0.02% 324
2021
Q4 		$129K Sell
381
-240
-39% -$92.8K 0.02% 277
2021
Q3 		$271K Buy
621
+270
+77% +$94.2K 0.07% 197
2021
Q2 		$123K Buy
+351
New +$136K 0.02% 328

Other funds holding CUE

PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

WealthShield Partners's CUE Position: Q2 2022 in Review

WealthShield Partners sold out of Cue Biopharma (CUE) in Q2 2022, closing a stake of 998 shares — an estimated $146K sold.

WealthShield Partners first reported a position in CUE in Q2 2021 and held it in 4 quarters. The position peaked at $271K in Q3 2021. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2022.

  • WealthShield Partners reported no remaining Cue Biopharma position as of Q2 2022 after selling out during the quarter.
  • WealthShield Partners sold 998 Cue Biopharma shares in Q2 2022, an estimated $146K.
  • WealthShield Partners first reported a position in Cue Biopharma in Q2 2021 and held it in 4 quarters.
  • WealthShield Partners's Cue Biopharma position peaked at $271K in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2022.

Based on WealthShield Partners's 13F filing for Q2 2022, filed 11 Aug 2022.